vildagliptin galenicum tablett
galenicum health s.l.u. - vildagliptiin - tablett - 50mg 30tk; 50mg 336tk; 50mg 90tk; 50mg 112tk; 50mg 180tk; 50mg 60tk
glibenese gits toimeainet prolongeeritult vabastav tablett
pfizer europe ma eeig - glipisiid - toimeainet prolongeeritult vabastav tablett - 5mg 30tk
glibenese gits toimeainet prolongeeritult vabastav tablett
pfizer europe ma eeig - glipisiid - toimeainet prolongeeritult vabastav tablett - 10mg 30tk
octreotide csc süstelahus
gp-pharm s.a. - oktreotiid - süstelahus - 100mcg 1ml 1ml 5tk
octreotide csc süstelahus
gp-pharm s.a. - oktreotiid - süstelahus - 50mcg 1ml 1ml 5tk
octreotide csc süstelahus
gp-pharm s.a. - oktreotiid - süstelahus - 500mcg 1ml 1ml 5tk
baqsimi
eli lilly nederland b.v. - glucagon - diabeet mellitus - pankrease hormoonid, hormoonid glycogenolytic - baqsimi on näidustatud ravi raskeid hypoglycaemia täiskasvanutel, noorukitel ja lastel vanuses 4 aastat ja enam, kellel diabeet.
mounjaro
eli lilly nederland b.v. - tirzepatide - suhkurtõbi, tüüp 2 - diabeetis kasutatavad ravimid - mounjaro is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise- as monotherapy when metformin is considered inappropriate due to intolerance or contraindications- in addition to other medicinal products for the treatment of diabetes. for study results with respect to combinations, effects on glycaemic control and the populations studied, see sections 4. 4, 4. 5 ja 5.
sandostatin süste-/infusioonilahus
novartis baltics sia - oktreotiid - süste-/infusioonilahus - 0,1mg 1ml 1ml 10tk; 0,1mg 1ml 1ml 6tk; 0,1mg 1ml 1ml 3tk; 0,1mg 1ml 1ml 20tk; 0,1mg 1ml 1ml 5tk
galvus
novartis europharm limited - vildagliptiin - suhkurtõbi, tüüp 2 - diabeetis kasutatavad ravimid - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control.